Last reviewed · How we verify
Prasugrel based standard DAPT
Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).
Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT). Used for Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI), Reduction of thrombotic cardiovascular events in patients with ACS.
At a glance
| Generic name | Prasugrel based standard DAPT |
|---|---|
| Sponsor | Research Maatschap Cardiologen Rotterdam Zuid |
| Drug class | P2Y12 receptor antagonist (thienopyridine) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Prasugrel is a thienopyridine prodrug that is metabolized to an active metabolite, which irreversibly binds to the P2Y12 adenosine diphosphate receptor on platelets. This prevents platelet activation and aggregation. When combined with aspirin in a DAPT regimen, it reduces thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI)
- Reduction of thrombotic cardiovascular events in patients with ACS
Common side effects
- Bleeding
- Thrombotic thrombocytopenic purpura (TTP)
- Dyspnea
- Bradycardia
Key clinical trials
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) (PHASE4)
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: